Tolerability, Safety, and Efficacy of Tedizolid as Oral Treatment for Bone and Joint Infections
Status:
Active, not recruiting
Trial end date:
2022-01-01
Target enrollment:
Participant gender:
Summary
The problem of interest is that doctors are looking for new antibiotic treatments for bone
and joint infections. Treatment for bone and joint infection is not standardized, which
allows a wide range of antibiotic therapy to potentially be given. A type of bacteria called
S. aureus is the most common cause of bone and joint infection. Methicillin resistant S.
aureus (MRSA) is a type of bacteria that is not killed by some antibiotics, and it is
increasingly common in U.S. and non-U.S. medical centers. This problem will be studied by
investigating whether an antibiotic called tedizolid is tolerable, safe and effective to
treat bone and joint infections.
Phase:
Phase 2
Details
Lead Sponsor:
Los Angeles Biomedical Research Institute Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center